LUCD vs. TMCI, DCTH, BFLY, RXST, SNWV, CLPT, NPCE, DRTS, TCMD, and SKIN
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Treace Medical Concepts (TMCI), Delcath Systems (DCTH), Butterfly Network (BFLY), RxSight (RXST), Sanuwave Health (SNWV), ClearPoint Neuro (CLPT), NeuroPace (NPCE), Alpha Tau Medical (DRTS), Tactile Systems Technology (TCMD), and Beauty Health (SKIN). These companies are all part of the "medical equipment" industry.
Lucid Diagnostics vs. Its Competitors
Treace Medical Concepts (NASDAQ:TMCI) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
In the previous week, Lucid Diagnostics had 3 more articles in the media than Treace Medical Concepts. MarketBeat recorded 4 mentions for Lucid Diagnostics and 1 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.67 beat Lucid Diagnostics' score of 1.05 indicating that Treace Medical Concepts is being referred to more favorably in the media.
Lucid Diagnostics has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 27.7% of Treace Medical Concepts shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Treace Medical Concepts currently has a consensus target price of $9.83, indicating a potential upside of 27.71%. Lucid Diagnostics has a consensus target price of $3.55, indicating a potential upside of 222.73%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Treace Medical Concepts.
Treace Medical Concepts has a net margin of -23.01% compared to Lucid Diagnostics' net margin of -1,476.35%. Lucid Diagnostics' return on equity of 0.00% beat Treace Medical Concepts' return on equity.
Treace Medical Concepts has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
Summary
Lucid Diagnostics beats Treace Medical Concepts on 9 of the 16 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:LUCD) was last updated on 8/24/2025 by MarketBeat.com Staff
MarketBeat All Access